OTCMKTS:BIOAF - biOasis Technologies Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.3450 +0.01 (+2.99 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$0.3320
Today's Range$0.34 - $0.3450
52-Week Range$0.3190 - $0.9350
Volume7,500 shs
Average Volume8,920 shs
Market Capitalization$22.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program. It also has a strategic collaboration with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Receive BIOAF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:BIOAF
CUSIPN/A
Phone604-295-7014

Debt

Debt-to-Equity RatioN/A
Current Ratio5.17
Quick Ratio5.17

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$460,000.00
Price / Sales42.62
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book34.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,130,000.00
Net Margins-1,517.77%
Return on Equity-243.43%
Return on Assets-215.80%

Miscellaneous

EmployeesN/A
Outstanding Shares56,830,000
Market Cap$22.73 million

biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions

What is biOasis Technologies' stock symbol?

biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."

How were biOasis Technologies' earnings last quarter?

biOasis Technologies Inc (OTCMKTS:BIOAF) announced its quarterly earnings data on Monday, July, 30th. The company reported ($0.02) EPS for the quarter. The company earned $0.04 million during the quarter. biOasis Technologies had a negative return on equity of 243.43% and a negative net margin of 1,517.77%. View biOasis Technologies' Earnings History.

When is biOasis Technologies' next earnings date?

biOasis Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for biOasis Technologies.

Who are some of biOasis Technologies' key competitors?

Who are biOasis Technologies' key executives?

biOasis Technologies' management team includes the folowing people:
  • Dr. Mark Day, CEO, Pres, Chief Scientist & Director
  • Mr. Christopher P. Lowe, Chief Financial Officer and Board Advisor (Age 47)
  • Ms. Catherine London, Exec. VP and Head of Corp. Communications & Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer

Has biOasis Technologies been receiving favorable news coverage?

Media coverage about BIOAF stock has trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. biOasis Technologies earned a media and rumor sentiment score of 0.21 on Accern's scale. They also gave media headlines about the company an impact score of 47.40 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for biOasis Technologies.

How do I buy shares of biOasis Technologies?

Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is biOasis Technologies' stock price today?

One share of BIOAF stock can currently be purchased for approximately $0.3450.

How big of a company is biOasis Technologies?

biOasis Technologies has a market capitalization of $22.73 million and generates $460,000.00 in revenue each year.

How can I contact biOasis Technologies?

biOasis Technologies' mailing address is 10691 SHELLBRIDGE WAY SUITE 130, RICHMOND A1, V6X 2W8. The company can be reached via phone at 604-295-7014 or via email at [email protected]


MarketBeat Community Rating for biOasis Technologies (OTCMKTS BIOAF)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  57
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BIOAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.